Regeneron Crashes 7% On Major Miss For Blockbuster Eye Drug

Sanofi Selling Long-Standing Stake in Regeneron for $13 Billion

Regeneron stock sinks over trial data for smoker's lungs drug

Regeneron Pharmaceuticals, Inc. : Baird n'est pas inspiré par le dossier

Regeneron Pharmaceuticals, Inc.: Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron CEO: More opportunities to grow Eylea